{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T21:11:36Z","timestamp":1793481096458,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxicology in Vitro"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1016\/j.tiv.2010.04.007","type":"journal-article","created":{"date-parts":[[2010,4,28]],"date-time":"2010-04-28T13:12:46Z","timestamp":1272460366000},"page":"1417-1425","source":"Crossref","is-referenced-by-count":33,"title":["Screening for phospholipidosis induced by central nervous drugs: Comparing the predictivity of an in vitro assay to high throughput in silico assays"],"prefix":"10.1016","volume":"24","author":[{"given":"Natalie","family":"Mesens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margino","family":"Steemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert R.","family":"Verheyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freddy","family":"Van Goethem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaques","family":"Van Gompel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tiv.2010.04.007_bib5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1006\/taap.1999.8688","article-title":"Lysosomal trapping as an important mechanism involved in the cellular distribution of perazine and in pharmacokinetic interaction with antidepressants","volume":"158","author":"Daniel","year":"1999","journal-title":"Toxicology and Applied Pharmacology"},{"key":"10.1016\/j.tiv.2010.04.007_bib6","series-title":"The Interaction of Drugs and Subcellular Components in Animal Cells","author":"De Duve","year":"1968"},{"key":"10.1016\/j.tiv.2010.04.007_bib7","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.etp.2007.01.004","article-title":"Cell-based fluorescence assay for evaluation of new-drugs potential for phospholipidosis in an early stage of drug development","volume":"58","author":"Fujimura","year":"2007","journal-title":"Experimental and Toxicological Pathology (Official Journal of the Gesellschaft f\u00fcr Toxikologische Pathologie)"},{"key":"10.1016\/j.tiv.2010.04.007_bib8","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jbspin.2007.06.006","article-title":"Gaucher disease","volume":"75","author":"Guggenbuhl","year":"2008","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.tiv.2010.04.007_bib11","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.3109\/00498259009046842","article-title":"Human accumulation potential of xenobiotics: potential of catamphiphilic drugs to promote their accumulation via inducing lipidosis or mucopolysaccharidosis","volume":"20","author":"Hein","year":"1990","journal-title":"Xenobiotica"},{"key":"10.1016\/j.tiv.2010.04.007_bib13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/toxsci\/kfj067","article-title":"Establishment of an in vitro high-throughput screening assay for detecting phospholipidosis-inducing potential","volume":"90","author":"Kasahara","year":"2006","journal-title":"Toxicological Sciences"},{"key":"10.1016\/j.tiv.2010.04.007_bib13a","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/jps.20792","article-title":"Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications","volume":"4","author":"Kaufmann","year":"2007","journal-title":"Journal of Pharmaceutical Science"},{"key":"10.1016\/j.tiv.2010.04.007_bib14","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/978-3-0348-8845-5_7","article-title":"The application of high-throughput screening to novel lead discovery","volume":"51","author":"Kenny","year":"1998","journal-title":"Progress in Drug Research"},{"key":"10.1016\/j.tiv.2010.04.007_bib16","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nrd2378","article-title":"The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates","volume":"6","author":"Kramer","year":"2007","journal-title":"Nature Reviews Drug Discovery"},{"key":"10.1016\/j.tiv.2010.04.007_bib17","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2174\/138620708783877726","article-title":"High throughput screening informatics","volume":"11","author":"Ling","year":"2008","journal-title":"Combinatorial Chemistry & High Throughput Screening"},{"key":"10.1016\/j.tiv.2010.04.007_bib21","first-page":"49","article-title":"Drug-induced lysosomal storage disorders","volume":"48","author":"L\u00fcllmann-Rauch","year":"1979","journal-title":"Frontiers of Biology"},{"key":"10.1016\/j.tiv.2010.04.007_bib22","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/bod.2510090602","article-title":"The potential role of lysosomes in tissue distribution of weak bases","volume":"9","author":"MacIntyre","year":"1988","journal-title":"Biopharmaceutics & Drug Deposition"},{"key":"10.1016\/j.tiv.2010.04.007_bib23","unstructured":"Mesens, N., Verbeeck, J., Rouan, M., Vanparys, P., 2007. Elucidating the role of M2 in the preclinical safety profile of TMC207. Abstract on the 38th Union World Conference on Lung Health, Cape Town, South Africa."},{"key":"10.1016\/j.tiv.2010.04.007_bib24","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.tiv.2008.11.010","article-title":"A 96-well flow cytometric screening assay for detecting in vitro phospholipidosis-induction in the drug discovery phase","volume":"23","author":"Mesens","year":"2009","journal-title":"Toxicology in Vitro"},{"key":"10.1016\/j.tiv.2010.04.007_bib25","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1517\/17425255.2.5.687","article-title":"In vitro assays and biomarkers for drug-induced phospholipidosis","volume":"2","author":"Monteith","year":"2006","journal-title":"Expert Opinion on Drug Metabolism & Toxicology"},{"key":"10.1016\/j.tiv.2010.04.007_bib27","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1021\/ci6004542","article-title":"Evaluation of a published in silico model and construction of a novel Bayesian model for predicting phospholipidosis inducing potential","volume":"47","author":"Pelletier","year":"2007","journal-title":"Journal of Chemical Information and Modelling"},{"key":"10.1016\/j.tiv.2010.04.007_bib28","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0940-2993(04)70180-3","article-title":"Use of physicochemical calculation of pKa and ClogP to predict phospholipidosis-inducing potential: a case study with structurally related piperazines","volume":"55","author":"Ploemen","year":"2004","journal-title":"Experimental and Toxicological Pathology"},{"key":"10.1016\/j.tiv.2010.04.007_bib30","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1517\/14740338.5.4.567","article-title":"Drug-induced phospholipidosis: issues and future directions","volume":"5","author":"Reasor","year":"2006","journal-title":"Expert Opinion on Drug Safety"},{"key":"10.1016\/j.tiv.2010.04.007_bib31","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0065-2660(01)44083-1","article-title":"Molecular epidemiology of Tay-Sachs disease","volume":"44","author":"Risch","year":"2001","journal-title":"Advances in Genetics"},{"key":"10.1016\/j.tiv.2010.04.007_bib33","first-page":"133","article-title":"Inherited neuropathies related to disorders of lipid metabolism","volume":"48","author":"Thomas","year":"1988","journal-title":"Advances in Neurology"},{"key":"10.1016\/j.tiv.2010.04.007_bib34","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2131\/jts.31.315","article-title":"Physicochemical and cell-based approach for early screening of phospholipidosis-inducing potential","volume":"31","author":"Tomizawa","year":"2006","journal-title":"The Journal of Toxicological Sciences"},{"key":"10.1016\/j.tiv.2010.04.007_bib35","doi-asserted-by":"crossref","first-page":"5518","DOI":"10.1016\/j.febslet.2006.06.008","article-title":"Lipid imbalance in the neurological disorder, Niemann-Pick C disease","volume":"580","author":"Vance","year":"2006","journal-title":"FEBS Letters"},{"key":"10.1016\/j.tiv.2010.04.007_bib37","unstructured":"Williard, J., 2008. FDA phospholipidosis working group: preliminary results and developing options. In: Paper Presented at the Continuing Course on phospholipidosis, 2008 STP, San Francisco."}],"container-title":["Toxicology in Vitro"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887233310000901?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887233310000901?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,11]],"date-time":"2018-12-11T14:51:19Z","timestamp":1544539879000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887233310000901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S0887233310000901"],"URL":"https:\/\/doi.org\/10.1016\/j.tiv.2010.04.007","relation":{},"ISSN":["0887-2333"],"issn-type":[{"value":"0887-2333","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}